We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ALK

News List

Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents worldpharmanews
May 21, 2019
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents.
NICE backs Takeda’s Alunbrig in second-line lung cancer pharmaceutical-technology
February 20, 2019
The UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has revised its previous rejection of Takeda’s Alunbrig (brigatinib) for adults with anaplastic lymphoma kinase ....
ALK appoints new Head of Product Supply firstwordpharma
January 13, 2019
Carsten Hellmann, President & CEO, said: "Christian's experience and leadership qualities make him ideally suited to his new role and I would like to congratulate him on his appointment and welcome him as a member of ALK's management team, where his exper
Roche's Alecensa topples Pfizer's Xalkori in Asian patients with ALK+ advanced lung cancer pharmafile
November 01, 2018
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small cell lung cancer, Roche unveiled a second wave of findings at the European ...